A Phase 1b, Open-Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety , Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 in Subjects with Advanced Solid Tumors

Project: Research

Project Description

NMA Reference Number: HREC/15/MH/334.
SSA Reference Number: SSA/15/MonH/208.
Monash Health HREC Ref: 15537X
StatusActive
Effective start/end date25/03/19 → 24/03/24
View all
View less

Keywords

  • clinical trial
  • phase 1 study
  • advanced solid tumor
  • treatment efficacy
  • clinical trial
  • phase 1 study
  • advanced solid tumor
  • treatment efficacy
  • clinical trial
  • phase 1 study
  • advanced solid tumor
  • treatment efficacy